ReviewClinical medicine (London, England)2013
Pharmacological treatment of chronic stable angina pectoris.
Review in Clinical medicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Ranolazine for stable angina pectoris.The Cochrane database of systematic reviews · 2017Pooled it
- Effectiveness and Safety of Acupoint Application of Guan Xin Su He Pill () for Patients with Chronic Stable Angina Pectoris: A Multi-Center, Randomized Controlled Trial.Chinese journal of integrative medicine · 2021Trial
- Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina.Scientific reports · 2014Trial
- Trial
- Designing the User Interface of a Nitroglycerin Dose Titration Decision Support System: User-Centered Design Study.Applied clinical informatics · 2024Article
- Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study.Journal of clinical medicine · 2024Article
- Impact of Bioactive Compounds in the Management of Various Inflammatory Diseases.Current pharmaceutical design · 2024Review
- Effects of Personalized Nursing plus Dietary Nursing Management on LP-PLA2, Hcy Levels, and Quality of Life in Elderly Patients with Acute Coronary Syndrome.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- A Systematic Review on the Economic Evaluations Evidence of Enhanced External Counter-Pulsation (EECP) for Managing Chronic Stable Angina.Medical journal of the Islamic Republic of Iran · 2022Review
- Multicomponent Cardiac Rehabilitation and Cardiovascular Outcomes in Patients With Stable Angina: A Systematic Review and Meta-analysis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021Article
- Outpatient Management of Patients With Angina With No Obstructive Coronary Arteries: How to Come to a Proper Diagnosis and Therapy.Frontiers in cardiovascular medicine · 2021Review
- Article
- Treatment of stable ischaemic heart disease: the old and the new.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- The effectiveness of moxibustion for stable angina pectoris: A meta-analysis and trial sequential analysis protocol.Medicine · 2019Article
- Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.European cardiology · 2018Review
- Article
- Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.BMC health services research · 2016Article
- Vasodilator Therapy: Nitrates and Nicorandil.Cardiovascular drugs and therapy · 2016Review
- The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2016Review
- Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.BMC health services research · 2015Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic stable angina is the most common manifestation of ischaemic heart disease in the developed world and is associated with impaired quality of life and increased mortality. The pathogenesis of stable angina is complex and often, albeit not always, involves flow-limiting epicardial coronary artery stenoses (atheromatous plaques) that reduce the ability of the coronary circulation to deliver appropriate blood supply to the myocardium. The coronary microcirculation can also play an important role. An imbalance between myocardial oxygen supply and metabolic oxygen demand causes the symptoms of angina pectoris and represents a major therapeutic target. Rational treatment requires a multi-faceted approach combining lifestyle changes, aggressive management of modifiable coronary artery disease risk factors, pharmacological therapy and myocardial revascularisation when appropriate. Despite modern therapies, many patients continue to suffer from angina. Several new anti-anginal drugs have been introduced that might allow more effective symptom control. These novel agents have specific mechanisms of action and fewer side effects compared to conventional drugs. The combined use of traditional and novel treatments is likely to increase the proportion of patients who are managed successfully with medical therapy alone. This article briefly reviews recent advances in the pharmacological management of chronic stable angina pectoris, highlighting how an understanding of the prevailing pathogenic mechanisms in the individual patient can aid appropriate selection of therapeutic strategies and improve clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.